United States Patent 4,894,445: Scope, Claims, Expiration, and Technetium-99m Patent Landscape

U.S. Patent 4,894,445 covers a kit-oriented method for making radioactive-metal coordination complexes by replacing copper in a lyophilized copper-isonitrile adduct with a radioactive metal. Its commercially relevant center is technetium-99m complexes using substituted butyl isonitrile ligands, including the ligand family used for technetium Tc-99m sestamibi.

The patent issued January 16, 1990. Because it predates the Uruguay Round Agreements Act patent-term transition, its ordinary term was 17 years from issuance, placing expiration on or about January 16, 2007, absent an unusual adjustment or disclaimer. The patent is therefore expired and cannot presently block manufacture, use, sale, or importation in the United States.

What does U.S. Patent 4,894,445 cover?

The patent covers a preparation method, not a broad standalone claim to every technetium-isonitrile complex.

The core process has five required elements:

An isonitrile ligand.
A soluble copper adduct of that ligand.
A lyophilized form of the copper adduct.
A radioactive metal added in a suitable solvent.
Replacement of copper by the radioactive metal to form the final coordination complex.

The broadest claim, claim 1, identifies a large group of radioactive metals:

Technetium
Ruthenium
Cobalt
Platinum
Iron
Osmium
Iridium
Tungsten
Rhenium
Chromium
Molybdenum
Manganese
Nickel
Rhodium
Palladium
Niobium
Tantalum

Claims 2 through 5 narrow the invention to technetium, technetium-99m, and specified butyl-based isonitrile ligands. Claims 6 and 7 narrow the copper precursor by requiring a defined copper-adduct structure and selected bidentate chelating ligands.

Claim architecture

Claim	Subject matter	Practical scope
1	Preparation of radioactive-metal isonitrile complexes using a lyophilized soluble copper adduct	Broad process claim covering the listed radioactive metals
2	Claim 1 limited to technetium	Technetium-specific process
3	Claim 2 limited to Tc-99m	Nuclear-medicine preparation process
4	Claim 3 with a butyl isonitrile ligand	Unsubstituted butyl embodiment
5	Claim 3 with substituted butyl isonitrile containing an alkyl ether or ester	Commercially relevant substituted-ligand class
6	Claim 1 using `[Cu(CNR)2Y]X`	Defined copper precursor
7	Claim 6 with phenanthroline, diimine, or bipyridine-type chelating ligand	Narrow precursor-structure claim

The claims should be read as process claims requiring the claimed preparation sequence. A party that purchases a finished technetium complex and merely administers it would not ordinarily practice these claims. A party that makes the complex by a different route, without the claimed lyophilized copper adduct, would also have a noninfringement position based on the claim language.

What technical problem does the patent address?

Technetium-99m has a short physical half-life and is typically supplied from a generator or other radiopharmaceutical source shortly before clinical use. A commercial preparation method must support:

Rapid radiolabeling.
High labeling yield.
Consistent product quality.
Room-temperature or refrigerated storage before reconstitution.
A kit format suitable for hospital radiopharmacies.
Low residual copper and other impurities.
Reproducible formation of the desired technetium complex.

The patent’s solution is a lyophilized copper surrogate. The copper adduct is prepared and stabilized in advance. When reconstituted with a technetium-99m source, technetium displaces copper and forms the target radioactive complex.

This approach is materially different from claiming only the final radiopharmaceutical. It protects a manufacturing and kit workflow that can simplify radiolabeling at the point of use.

How should the principal terms in claim 1 be interpreted?

“Isonitrile ligand”

An isonitrile ligand contains the functional group represented by CNR. The ligand coordinates to a metal through the isonitrile carbon. The claim does not limit the ligand to one specific molecular structure at the claim 1 level, although later claims narrow the ligand to butyl and substituted butyl radicals.

The phrase “R is a suitable organic radical” in claim 6 is broad but not unlimited. The radical must support formation of the claimed copper adduct and the subsequent radioactive-metal complex. A court would likely examine the specification for structural and functional boundaries.

“Soluble copper adduct”

The copper compound must be sufficiently soluble to participate in the radiolabeling reaction. A non-soluble copper salt or an insoluble copper-ligand material would provide a potential limitation-based defense.

The phrase also indicates that copper is acting as a removable metal center or precursor metal. The claim does not merely require the presence of copper somewhere in the kit.

“Lyophilized”

Lyophilization means freeze-drying. This limitation is important. A liquid copper precursor, a non-lyophilized powder, or a separately supplied ligand and copper salt may fall outside claim 1 unless the accused arrangement is legally treated as the claimed lyophilized adduct.

The lyophilized requirement provides a direct distinction from conventional liquid-phase synthesis and from some later kit designs.

“Admixing”

The claims require mixing the lyophilized copper adduct with the radioactive metal in a suitable solvent. The accused method must therefore include a physical or process step that brings the relevant components together.

“Replace said copper”

The claim requires metal exchange. The radioactive metal must displace copper in the coordination complex. Merely mixing a copper compound with a radioactive compound without formation of the claimed radioactive coordination complex would not satisfy the process as written.

What do claims 2 through 5 add for technetium-99m products?

Claims 2 and 3 create a focused path to technetium-99m radiopharmaceutical manufacturing.

Claim 4 covers an isonitrile ligand with a butyl radical. Claim 5 expands the commercially important substituted-butyl category to ligands containing an alkyl ether or alkyl ester substitution.

The substituted-butyl language is relevant to technetium-99m sestamibi-type chemistry. Sestamibi is a lipophilic cationic technetium complex using methoxyisobutyl isonitrile ligands. A formulation using a methoxy-substituted isobutyl isonitrile would be evaluated against the structural and functional limits of claim 5, rather than against the broad radioactive-metal language alone.

The claims do not expressly recite:

The final product’s clinical indication.
Myocardial perfusion imaging.
Breast imaging.
A particular vial configuration.
A particular dose.
A particular imaging protocol.
A specific oxidation state of technetium.
A specific number of isonitrile ligands in the final technetium complex.

Those omissions matter. The patent’s center of gravity is the preparation process and precursor chemistry.

What does claim 6 and claim 7 protect?

Claim 6 requires a copper adduct with the formula:

[Cu(CNR)2Y]X

The elements are:

Copper.
Two isonitrile ligands.
A bidentate chelating ligand represented by Y.
A counterion represented by X.

Claim 7 limits Y to:

Phenanthroline.
Substituted phenanthroline.
Diimine.
Substituted diimine.
Bipyridine.
Substituted bipyridine.

These claims are narrower than claim 1 but may be more technically focused. A process using a copper precursor outside the claimed formula, or using a monodentate auxiliary ligand rather than one of the listed bidentate systems, would require separate infringement analysis.

The use of “selected from the group consisting of” generally creates a closed list for claim 7. An accused chelating ligand that is chemically similar but not within the listed categories would not automatically satisfy the claim.

What patents protect technetium-99m sestamibi and related products?

The relevant estate is broader than U.S. Patent 4,894,445. It can be divided into four patent families.

1. Precursor and radiolabeling-process patents

These patents cover:

Copper-isonitrile precursor compounds.
Freeze-dried or lyophilized kit components.
Metal-exchange labeling.
Solvent and heating conditions.
Purification or quality-control procedures.

U.S. Patent 4,894,445 belongs primarily to this category.

2. Final-complex and composition patents

A separate family may claim:

The technetium coordination complex itself.
Specific ligand stoichiometry.
Defined counterions.
Defined radionuclide purity.
Stable pharmaceutical compositions.
Diagnostic kits containing the final complex or its precursor.

A final-product patent can create a different infringement risk from a process patent. A manufacturer may avoid an expired preparation claim but still need to evaluate later composition or formulation rights. For the sestamibi field, the principal composition and kit patents were filed in the late 1980s and early 1990s and have also reached the end of their ordinary terms.

3. Method-of-use patents

Method-of-use claims may cover administration of technetium-99m complexes for:

Myocardial perfusion imaging.
Detection of ischemia or infarction.
Breast lesion imaging.
Parathyroid imaging.
Tumor or tissue perfusion imaging.

These claims are distinct from the manufacturing claims in Patent 4,894,445. They require the claimed diagnostic use, patient population, imaging method, or disease indication.

Because many early radiopharmaceutical use patents have expired, current commercial risk generally depends more on regulatory status, manufacturing controls, trade secrets, and product-specific patents than on the original Patent 4,894,445 claims.

4. Formulation, container, and manufacturing patents

Later rights may address:

Vial closure systems.
Stabilizers and excipients.
Reconstitution conditions.
Kit shelf life.
Sterile manufacturing.
Generator eluate handling.
Radiochemical purity testing.
Automated compounding systems.

These rights may be important even when the active coordination chemistry is no longer patent-protected. A generic or follow-on manufacturer must distinguish the expired active-ingredient estate from any later, still-live manufacturing or device patents.

When did U.S. Patent 4,894,445 lose exclusivity?

The patent issued January 16, 1990. Under the pre-Uruguay Round patent term applicable to the patent, the ordinary term was 17 years from issuance. The resulting expiration date was approximately January 16, 2007. The USPTO patent record should control for any patent-term adjustment, disclaimer, or other term modification. [1]

The practical result is clear:

Event	Date
Patent issued	January 16, 1990
Ordinary 17-year term	January 16, 2007
Current enforceability	Expired
Current Paragraph IV relevance	None for this patent
Current Orange Book blocking effect	None based on this patent

The patent cannot support a new infringement action for conduct occurring after expiration. It can remain relevant historically, however, for freedom-to-operate reviews, prosecution history, claim construction, and prior-art analysis.

What is the Orange Book status of U.S. Patent 4,894,445?

Patent 4,894,445 is not a currently enforceable Orange Book patent. An expired patent cannot provide present-day Hatch-Waxman exclusivity.

The Orange Book lists FDA-approved drug products and certain patents submitted by NDA holders. It does not provide a complete register of every patent relevant to a drug, every manufacturing right, or every historical radiopharmaceutical patent. A patent can be relevant to a product without being listed in the Orange Book.

For technetium-99m sestamibi products, the regulatory pathway is also atypical compared with a conventional small-molecule chronic medicine:

The product is a radiopharmaceutical kit.
The kit is combined with technetium-99m at or near the point of use.
The commercial product may be regulated through an NDA or abbreviated pathway depending on the product and regulatory history.
Radiochemical manufacturing and quality control are central to approval.
The short half-life of Tc-99m affects distribution and commercial supply.

FDA approval does not establish freedom to operate. Conversely, expiration of Patent 4,894,445 does not itself establish approval or substitutability. [2]

Are there Paragraph IV challenges to Patent 4,894,445?

No current Paragraph IV challenge can create a commercial barrier for Patent 4,894,445 because the patent expired in approximately 2007.

A Paragraph IV certification is relevant when an applicant asserts that a listed patent is invalid, unenforceable, or not infringed. It is a Hatch-Waxman mechanism tied to listed patents associated with an approved drug application. The mechanism has no practical blocking function for an expired patent.

Historical litigation or certification activity involving technetium-99m sestamibi products should not be conflated with current enforceability. A later patent, a patent covering a different kit configuration, or a method-of-use patent could have been challenged separately.

Which companies have challenged or competed in this field?

The commercial field has included originator and successor products associated with DuPont, Bristol-Myers Squibb, and other radiopharmaceutical suppliers. Cardiolite, the principal sestamibi product, became a major commercial product for myocardial perfusion imaging. Generic and multisource competition developed after the relevant early patent barriers expired.

Competition has generally involved:

Finished Tc-99m sestamibi kits.
Hospital radiopharmacy compounding.
Generic kit suppliers.
Competing myocardial perfusion agents.
Rubidium-82 and other PET or SPECT imaging products.
Alternative technetium-based imaging agents.

The principal competitive products are not direct substitutes in every clinical setting. Product selection depends on imaging equipment, reimbursement, generator access, logistics, hospital workflow, and physician preference.

How strong is the patent estate for Patent 4,894,445?

Historical strength

The patent had meaningful historical value because it combined:

Broad radioactive-metal language.
A practical radiolabeling process.
Lyophilized kit technology.
Copper-mediated metal exchange.
Technetium-99m dependent claims.
Ligand-specific claims relevant to commercial imaging agents.

The kit limitation could have been commercially important. A competing manufacturer using the same lyophilized copper-adduct exchange process may have faced infringement exposure even if it used a different final product name.

Current strength

Current enforceability is zero because the patent is expired. Its residual value is limited to:

Technical know-how disclosed in the patent.
Prior-art status.
Historical licensing analysis.
Claim interpretation in related patent families.
Evidence concerning inventorship, priority, or obviousness in later disputes.

The expired patent does not create a current manufacturing monopoly.

Legal vulnerabilities that would have mattered during the term

The broadest claim presented potential validity questions involving:

Enablement across the full list of radioactive metals.
Written description support for the full ligand and metal scope.
Definiteness of “suitable organic radical,” “appropriate counter ion,” and “suitable solvent.”
Anticipation by earlier copper-transfer or metal-exchange chemistry.
Obviousness based on radiolabeling kits and coordination chemistry.

The narrower technetium-99m and ligand-specific claims would likely have been more commercially significant and potentially more defensible than the full claim 1 genus.

What generic entry risks exist today?

For the specific rights in Patent 4,894,445, there is no current patent-based entry risk. A manufacturer can no longer be enjoined for practicing the claimed process solely because of this patent.

Current entry risks are more likely to arise from:

Risk category	Present relevance
Expired active-ingredient patents	No blocking effect
Later formulation patents	Product- and claim-specific
Later process patents	Relevant if still unexpired
Method-of-use patents	Relevant only for claimed diagnostic uses
FDA approval requirements	High
Sterility and radiochemical quality	High
Manufacturing know-how	High
Supply of Tc-99m	High
Trademark and trade dress	Separate commercial issue
Patent litigation under 35 U.S.C. § 271(e)(2)	Depends on current listed patents

A generic entrant still must address FDA requirements, chemistry-manufacturing-controls documentation, sterile production, radionuclide handling, validated radiochemical purity, and hospital distribution. Patent expiration removes one legal barrier but does not remove those operational barriers.

What manufacturing and intellectual-property barriers remain?

The technically difficult parts of commercial entry include:

Reproducible synthesis of the isonitrile ligand.
Control of copper-adduct composition.
Reliable lyophilization.
Rapid and complete technetium incorporation.
Control of free pertechnetate and colloidal technetium.
Control of residual copper and other metals.
Sterile filling and container closure.
Stability through the labeled kit shelf life.
Batch release testing.
Cold-chain and radiopharmacy distribution.
Compliance with radioactive-material regulations.

Some of these barriers may be protected by trade secrets rather than patents. Process parameters, impurity-control strategies, lyophilization cycles, and scale-up methods can retain commercial value after patent expiration.

How does Patent 4,894,445 compare with later patent strategies?

Issue	Patent 4,894,445	Later patent strategies
Main protection	Preparation method	Final product, formulation, use, or device
Key precursor	Lyophilized copper adduct	May use alternative precursors or direct labeling
Radionuclide scope	Broad list, narrowed by dependent claims	Often focused on Tc-99m or a defined product
Commercial focus	Radiolabeling kit chemistry	Product differentiation and regulatory lifecycle
Current status	Expired	Must be checked family by family
Orange Book value	No current blocking value	Depends on listing and expiration
Manufacturing significance	High historically	May remain high if later process claims survive

The patent’s broad chemical language should not be mistaken for continuing market exclusivity. In the current market, the more important questions are whether a supplier has a later unexpired patent, whether the product is FDA-approved, and whether the supplier controls a validated manufacturing process.

Key Takeaways

U.S. Patent 4,894,445 is a process patent for making radioactive-metal isonitrile complexes through a lyophilized soluble copper adduct.
Claims 2 through 5 focus the patent on technetium-99m and butyl or substituted-butyl isonitrile ligands.
Claims 6 and 7 narrow the copper precursor to specified chelating-ligand structures.
The patent issued January 16, 1990, and its ordinary term ended approximately January 16, 2007.
The patent is expired and has no current Paragraph IV or Orange Book blocking effect.
The patent historically supported kit-based radiolabeling technology relevant to technetium-99m sestamibi.
Current freedom-to-operate analysis must focus on later composition, formulation, method-of-use, manufacturing, and device patents.
FDA approval, sterility, radiochemical purity, Tc-99m supply, and manufacturing know-how remain material entry barriers.

FAQs

Can a company still practice the method in Patent 4,894,445?

Yes. The patent is expired, so the claimed method is generally available for practice in the United States, subject to other applicable patents, regulatory requirements, and non-patent restrictions.

Does Patent 4,894,445 claim Cardiolite by name?

No. The claims use chemical and process language rather than the Cardiolite trademark. Commercial relevance arises from the relationship between the claimed substituted butyl isonitrile chemistry and technetium-99m sestamibi-type radiopharmaceuticals.

Does the patent cover direct labeling of a ligand without copper?

The claims require a lyophilized soluble copper adduct and replacement of copper by the radioactive metal. A genuinely direct-labeling process without that precursor would not satisfy the literal process requirements.

Could a patent-expired technetium kit still be difficult to launch?

Yes. FDA approval, sterile radiopharmaceutical manufacturing, radionuclide handling, validated quality control, and reliable hospital distribution can impose substantial barriers even when the original patent estate has expired.

Are technetium-99m radiopharmaceuticals subject to biosimilar competition?

No. Biosimilar law applies to biological products. Technetium-99m sestamibi is a chemically defined radiopharmaceutical kit, so competition is generally analyzed through generic-drug, NDA, ANDA, or other applicable FDA pathways rather than the biosimilar pathway.

References

United States Patent and Trademark Office. (1990). U.S. Patent No. 4,894,445: Method for preparing radioactive metal complexes. https://patents.google.com/patent/US4894445
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book
U.S. Food and Drug Administration. (n.d.). Cardiolite kit for the preparation of technetium Tc 99m sestamibi injection: Prescribing information. FDA labeling database. https://www.accessdata.fda.gov/scripts/cder/daf/
United States Code, 35 U.S.C. §§ 154, 271(e). (2024). Patent term and pharmaceutical approval-related patent litigation provisions. https://uscode.house.gov/
U.S. Food and Drug Administration. (n.d.). Approved drug product database. https://www.accessdata.fda.gov/scripts/cder/daf/

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	63311	⤷ Start Trial
Australia	587484	⤷ Start Trial
Australia	6087886	⤷ Start Trial
Canada	1293729	⤷ Start Trial
Germany	3679116	⤷ Start Trial
Denmark	174300	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Summary for Patent: 4,894,445